ABSTRACT Background: The debate over a role for n23 long-chain polyunsaturated fatty acids (n23 PUFAs) in depressed mood continues. Objective: The objective was to update a previous systematic review and meta-analysis of published randomized controlled trials investigating the effects of n23 PUFAs on depressed mood and to explore potential sources of heterogeneity. Design: Eight databases were searched for trials that randomly assigned participants to receive n23 PUFAs/fish, measured depressed mood, used human participants, and included a comparison group up to April 2009. Results: Thirty-five randomized controlled trials were identified; 17 were not included in the previous review. The pooled standardized difference in mean outcome of the 29 trials that provided data to allow pooling (fixed-effects model) was 0.10 SD (95% CI: 0.02, 0.17) in those who received n23 PUFAs compared with placebo, with strong evidence of heterogeneity (I 2 = 65%, P , 0.01). The presence of funnel plot asymmetry suggested that publication bias was a likely source of this heterogeneity. Depressive symptom severity and participant diagnosis also explained some of the observed heterogeneity. Greater effects of n23 PUFAs were found in individuals with more-severe depressive symptoms. In trials that enrolled individuals with a diagnosed depressive disorder, the combined mean difference was 0.41 (95% CI: 0.26, 0.55), although evidence of heterogeneity was also found
INTRODUCTION
Debate over a role for n23 long-chain polyunsaturated fatty acids (n23 PUFAs) in depressive conditions continues. Biological evidence suggests a possible role for n23 PUFAs in various depressive conditions via various mechanistic pathways (1) (2) (3) . Ecologic and observational studies suggest that greater n23 PUFA intakes are associated with a reduced risk of depressive illness (4, 5) , cross-sectional evidence suggests associations between greater n23 PUFA status and reduced depressive symptomatology (6, 7) , and randomized controlled trials (RCTs) are available suggesting beneficial effects of n23 PUFAs compared with placebo (8) (9) (10) .
Ecologic and observational studies, however, are also available that suggest no association between n23 PUFAs and depressive illness (11, 12) or no association once confounders have been accounted for (13) , cross-sectional evidence suggesting limited or no associations is also available (14) , and RCTs have been published that suggest no benefits (15, 16) .
Attempts to combine the available evidence to date have resulted in the publication of 3 meta-analyses (17-19), 2 of which followed systematic reviews (17, 19) . That by Lin and Su (19) reported a beneficial effect of n23 PUFAs on depressive disorders of 0.69 SDs (P = 0.03), although considerable heterogeneity between studies and publication bias was also found. That conducted by ourselves (17) showed a beneficial effect of n23 PUFAs on depressed mood of 0.13 SDs (95% CI: 0.01, 0.25), again with strong evidence of heterogeneity and funnel plot asymmetry, but also suggested a beneficial effect of n23 PUFAs for individuals with a diagnosis of depressive illness (standardized mean difference: 0.57 SD; 95% CI: 0.37, 0.77) and no effect in those with no diagnosis (standardized mean difference: 20.13 SDs; 95% CI: 20.29, 0.03).
In relation to the effects of n23 PUFAs, an important distinction may exist between diagnosed depressive illness and the less severe, undiagnosed, or precursor "depressed mood." Differences in effects dependent on the degree of illness have also been suggested elsewhere (15) . Current studies of the relation, however, propose a linear association between n23 PUFA intake and depressive illness, potential mechanisms for an association again propose a linear effect, and evidence from ecologic, observational, and RCTs has been quickly extrapolated to provide population-based messages recommending reduced risk, prevention, and potential benefit from self-medication (20) (21) (22) .
Evidence of the effects of n23 PUFAs in depressed mood, however, is unclear and is clearly important on a population basis. The above meta-analyses are now also several years old and more trials have since been published.
This review aims to update our previous systematic review and meta-analysis to include all RCTs investigating the effects of n23 PUFA supplementation on depressed mood published by April 2009 and to use these data to systematically examine effects in individuals dependent on the severity of depressive illness and clinical diagnosis.
METHODS
The review was undertaken by using the same methods as those used previously (17) . In brief, published RCTs were identified by searching 8 databases [MEDLINE (http://ovidsp.tx.ovid.com/), EMBASE (http://ovidsp.tx.ovid.com/), PsycInfo (http://search. ebscohost.com/), CINAHL (http://search.ebscohost.com/), Biosis (http://apps.isiknowledge.com/), AMED (http://ovidsp.tx.ovid. com/), The Cochrane Controlled Trials Register (http://www3. interscience.wiley.com/), and The Cochrane Database of Systematic Reviews (http://www3.interscience.wiley.com/)] for all clinical trials investigating the effects of supplementation with n23 PUFAs ("n23," "omega-3," "w-3," "essential fatty acid," "ALA," "alpha-linolenic acid," "fish," "fatty fish," and "cod liver oil") on depressed mood ("depression," "depressive disorder," "depressed mood," "mood," "mood disorder," "affective disorder," "affect," "anxiety," "postpartum," "involutional," "dysthymic disorder," and "seasonal affective disorder") published from 2006 to April 2009. The term bipolar was also added to the search terms for depressed mood, and additional searches were conducted over all years of records for this term. Reference lists of relevant papers were also inspected to identify any additional trials.
Relevant articles were obtained and included in the review if studies used an exposure of n23 PUFAs/fish, included depressed mood as an outcome measure, enrolled human participants, included a comparison group, and reported a trial. All searches, trial identification, data abstraction, and tabulation were completed independently by 2 researchers. Discordances were discussed and resolved.
Statistical analysis
The methods and results of all additional identified trials were added to previous tables, and data from all trials reporting mean and SD data were formally combined (23) . Where means and SDs were not published, corresponding authors were contacted directly for this information. To include data from as many trials as possible, missing SD data for one trial were imputed from SD data from all other trials using the same measure for depression (24) . As previously, the standardized mean effect for all trials was calculated by using Hedges' adjusted g to correct for small sample bias (25) , and both random-and fixed-effects models were used to estimate the overall effect size, although the greatest weight was given to fixed-effects models because of the likely publication bias (23, 25, 26) . Heterogeneity was investigated by using Higgins' I 2 statistic (27, 28) . Three a priori potential sources of heterogeneity were identified: publication bias, severity of depressive symptoms, and participant diagnosis. Possible publication bias was investigated by drawing a funnel plot to look for funnel plot asymmetry (29) and meta-regression based on study size. Effects due to severity of depressive symptoms were investigated by using meta-regression based on standardized baseline depression scores. Effects due to participant diagnosis were investigated by conducting 2 metaregression analyses, where study effect size was predicted by using diagnosis of depressive disorder (present/absent) and by using diagnosis of psychiatric disorder (including depressive disorder) (present/absent), and sensitivity analyses based on participant diagnosis. To explore sources of possible bias, analyses were initially run by using all studies and were then rerun after omission of one large trial in which dietary advice intervention was used (30) , although previous analyses suggest that bias resulting from inclusion of this trial is unlikely (17) . Analyses were performed in Stata Version 8 (StataCorp Stata Statistical Software: release 8.0, 2003; Stata Corporation, College Station, TX) by using the "metan," "funnel," and "metareg" commands.
RESULTS
The updated searches from recent years resulted in the identification of 16 trials published since June 2006 and 1 trial published in 2002, which was not identified previously. Methods from these 17 trials, plus the 18 trials identified in the previous systematic review are displayed in Table 1 . Considerable variation between studies was found in number of participants, sex and age of participants, diagnosis of participants, dose and combination of n23 PUFAs used for supplementation, duration of supplementation, placebo used for comparison, measurement of depressed mood, and trial quality as assessed in terms of blinding, adequate allocation concealment, and the use of intention-to-treat analyses. The results as reported for all studies are shown in Table 2 .
Twenty-nine trials are included in the updated meta-analyses. Four trials (32, 40, 41, 44) could not be included because no means or SDs were available, and one trial (31) could not be included because no SDs were available and these could not be imputed because no other studies had used the same measure of depression. SDs were imputed for 3 trials (35, 36, 42) . Several studies reported results for more than one outcome measure of depressed mood. Results for the Hamilton Depression Rating Scale (HDRS), Beck Depression Inventory (BDI), or the Montgomery-Asberg Depression Rating Scale (MADRS) were used in the meta-analysis (in this order) as the most commonly used measures of mood in other studies. Where studies reported the use of 2 or 3 different interventions (10, 35, 36, 56, 58) , each intervention was included in the meta-analysis as a separate trial. For studies that enrolled 2 different populations (49) , each population was also included in the meta-analysis as a separate trial.
The pooled standardized difference in means (ie, the pooled effect size) using a fixed-effects model was 0.10 (95% CI: 0.02, 0.17) SD (P = 0.01), which suggests a beneficial effect of n23 PUFAs on depressed mood compared with placebo. The pooled standardized difference in means in a random-effects model was 0.26 (95% CI: 0.12, 0.40) SD (P , 0.01). Results of the meta-analysis using a fixed-effect model are summarized in Figure 1 . There was strong evidence of heterogeneity (I 2 = 65%, P , 0.001). Similar results were found after the removal of the trial by Ness et al (30) An ITT analysis is understood as an analysis of all participants who were randomly assigned to treatment.
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n-3 PUFAs AND DEPRESSED MOOD: UPDATED SYSTEMATIC REVIEW To explore this heterogeneity, a funnel plot was drawn and is shown in Figure 2 . The funnel plot shows evidence of considerable asymmetry. Meta-regression of study effect size, based on study size, showed an association (regression coefficient = 20.002; 95% CI: 20.004, 0.001; I 2 = 55%), where larger effect sizes are reported in smaller studies and smaller effect sizes are published from larger studies. Similar results were found after the removal of the trial by Ness et al (30) (regression coefficient = 20.004; 95% CI: 20.006, 20.001; I 2 = 53%).
Severity of depressive illness
Severity of depressive illness was a predictor of study standardized mean differences (regression coefficient: 0.09; 95% CI: 20.01, 20.17), where greater treatment effects were found in trials enrolling individuals with more severe depressive symptoms at baseline. Considerable heterogeneity, however, remained (I 2 = 65%, P , 0.01). Similar results were found after the removal of the trial by Ness et al (30) (regression coefficient: 0.11; 95% CI: 0.03, 0.19;, I 2 = 56%). A Forest plot of the initial meta-analysis organized by severity of depressive symptoms at baseline (standardized scores) is shown in Figure 3 .
Participant diagnosis
Diagnosis of depressive disorder was also a predictor of study standardized mean difference (regression coefficient: 20.45; 95% CI: 20.75, 20.15), as was diagnosis of psychiatric disorder (regression coefficient: 20.45; 95% CI: 20.74, 0.16), which suggests greater effects in those with a diagnosis of depressive illness and greater effects in those with any psychiatric illness including depression. Inclusion of diagnosis in the meta-analysis models also reduced heterogeneity a little, although considerable heterogeneity remained (depressive diagnosis: I 2 = 56%; psychiatric diagnosis: I 2 = 55%; P , 0.01). Similar results were . To investigate these effects further, sensitivity analyses were conducted on trials involving individuals with a diagnosis of depressive disorder, trials involving individuals with any other psychiatric diagnosis that was not a depressive disorder, trials involving individuals with no psychiatric illness and mildmoderate depressed mood, and trials involving individuals with no psychiatric illness and no depressed mood.
For trials that enrolled individuals with a diagnosis of depressive disorder (8-10, 15, 16, 34, 35, 38, 43, 46, 47, 49, 50, 52, 53, 55) , the pooled standardized difference in means using a fixed-effects model was 0.41 SD (95% CI: 0.26, 0.55), and the pooled standardized difference in means using a random-effects model was 0.57 SD (95% CI: 0.29, 0.85). There was strong evidence of heterogeneity (I 2 = 71%, P , 0.01). For trials that enrolled individuals with other psychiatric diagnoses, not depressive disorder (33, 36, 39, 45) , the pooled standardized difference in means using a fixed-effects model was 0.22 (95% CI: 20.01, 0.44) SDs, and the pooled standardized difference in means using a random-effects model was 0.24 (95% CI: 20.04, 0.52) SD. No evidence of heterogeneity was found (I 2 = 32%, P = 0.20). For trials that enrolled individuals with no psychiatric diagnoses, but mild-to-moderate depressed mood (48, 51, 54, 56, 59) , the pooled standardized difference in means using a fixedand a random-effects model was 0.02 (95% CI: 20.11, 0.14) SDs, with no evidence of heterogeneity (I 2 = 0%, P = 0.95). For trials that enrolled individuals with no psychiatric diagnoses and no depressed mood (30, 37, 42, 57, 58) , the pooled standardized difference in means using a fixed and a randomeffects model was 20.12 (95% CI: 20.25, 0.02) SDs, with no evidence of heterogeneity (I 2 = 0%, P = 0.78). Similar results were found after the removal of the trial by Ness et al (30) (standardized mean difference -fixed and random-effects model: 20.01 SD; 95% CI: 20.22, 0.19; I 2 = 0%; P = 0.95).
DISCUSSION
This updated review summarizes the current literature and contains 17 trials investigating the effects of n23 PUFA supplementation on depressed mood published since our previous review. Findings from the meta-analysis are remarkably similar to those previously found. The pooled estimate from the fixedeffects model provides little evidence of a beneficial effect of n23 PUFAs on depressed mood, and the combined estimate from the random-effects model suggests a beneficial effect of n23 PUFAs on depressed mood. An effect size of 0.1 SD (fixedeffects model) or 0.26 SD (random-effects model) is roughly equivalent to a change in depressed mood score on the HDRS of 0.5 or 1.3 points, respectively, assuming a mean treatment effect of x 6 5 points (Table 2) , whereas a change of 3 to 4 points has previously been suggested to be clinically relevant. Statistical evidence of substantial heterogeneity and funnel plot asymmetry n-3 PUFAs AND DEPRESSED MOOD: UPDATED SYSTEMATIC REVIEW also remain, questioning the reliability and validity of these findings and suggesting a need for considerable caution.
The funnel plot asymmetry suggests that the considerable heterogeneity observed results from publication bias (25, 29) , where positive effects of small studies are more likely to be published than are negative effects. Because of the bias inherent in random-effects models (25, 29) , the more informative analyses presented here are likely to be the fixed-effects analyses. These analyses suggest that there is little evidence of a beneficial effect of n23 PUFAs on depressed mood.
The investigation based on severity of depressive illness suggests that severity of illness may be an important effect modifier of the effect of n23 PUFAs on depressed mood, because n23 PUFAs were found to have greater effects in trials of individuals with more severe depressive symptoms. These findings suggest that whereas n23 PUFA supplementation may be beneficial for those with severe symptoms, it is unlikely to be of benefit for individuals with mild-to-moderate symptoms or for individuals aiming to prevent depression. A similar pattern of effects has also been found for pharmacologic treatments of depressive illness (83) .
Investigation of participant diagnosis suggests an important role for participant diagnosis in the effects of n23 PUFA supplementation on depressed mood. The meta-analysis that used only trials that enrolled populations with diagnosed depressive illness showed a beneficial effect of n23 PUFA supplementation on depressed mood, although substantial heterogeneity remained. These findings suggest that n23 PUFA supplementation may be beneficial for depressed mood in these populations, but the evidence for heterogeneity between studies suggests that this result may be unreliable and is far from definitive. Caution and further work is clearly needed to ascertain additional sources of heterogeneity. Large RCTs are required. All trials in depressed populations published so far have had sample sizes of ,100 participants per group, and, to our knowledge, only one larger trial is currently ongoing (http://www.controlled-trials.com/ isrctn).
Meta-analyses of trials involving individuals with other psychiatric diagnoses, individuals with no psychiatric diagnosis but mild-moderate depressed mood, and individuals with no psychiatric diagnosis and no depressed mood found no evidence of a beneficial effect of n23 PUFAs on depressed mood and no evidence of heterogeneity. These small combined effect sizes and the lack of heterogeneity suggest that n23 PUFA supplementation is unlikely to be beneficial for depressed mood in those without a diagnosis of depressive illness. The lack of heterogeneity in these analyses furthermore suggests that additional trials in these populations are unlikely to yield different results. An absence of effect in individuals without a diagnosis of depression suggests that n23 PUFA supplementation or increased consumption of foods rich in n23 PUFAs (such as oily fish) on a population-wide basis as a means of prevention, risk reduction, or self help may be futile.
Additional sources of the heterogeneity between studies are likely to exist. Work on n23 PUFA metabolism, for example, suggests that differences may occur between sexes and with age (84, 85) . Differences dependent on length of illness and medication treatment have also been suggested (33, 36, 45, 46) . Baseline intakes of n23 PUFAs and n26 PUFAs may also be important. Suggestions that n23 PUFA supplementation may be beneficial only in those with deficiencies or deficient PUFA metabolism have been made (54, 55) . Speculation that n23 PUFAs may have an indirect role in psychiatric conditions through the modulation of secondary messenger systems and n26 PUFA pathways has also been suggested (9, 10, 36, 55) . Type of PUFA, dose, duration, placebo comparison, measure of depression, and trial quality may also be important (8-10, 15, 18, 32, 35, 38, 86, 87) . These sources of heterogeneity were not investigated here because of a lack of available studies, but investigation of the causes of positive and negative effects in different studies remains important.
Considering the many potential sources of heterogeneity, a reliable combined estimate of effects of n23 PUFAs on depressed mood is still difficult to achieve. It is unfortunate that suitable data were not available to allow inclusion of all trials in the meta-analyses.
In summary, whereas trial evidence investigating the effects of n23 PUFAs on depressed mood has increased, the evidence that is available is difficult to summarize and evaluate because of the heterogeneous nature of the populations studied and the interventions used. Trials conducted in individuals with a diagnosis of depressive illness provide some evidence of a beneficial effect of n23 PUFA supplementation, but no evidence is available suggesting a benefit of n23 PUFA supplementation in individuals without a diagnosis of depressive disorder. Additional large, well-conducted studies in depressed populations are warranted, but similar studies in individuals with no diagnosis are unlikely to add to this field.
